Evidence map›Paper›PMID 35041511›Full record

ArticleAntimicrobial agents and chemotherapy2022

Transcriptomics Reveals How Minocycline-Colistin Synergy Overcomes Antibiotic Resistance in Multidrug-Resistant Klebsiella pneumoniae.

Thea Brennan-Krohn, Alexandra Grote, Shade Rodriguez, James E Kirby, Ashlee M Earl

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antimicrobial agents and chemotherapy · 2025
    Article
  5. Colistin: Lights and Shadows of an Older Antibiotic.Molecules (Basel, Switzerland) · 2024
    Review
  6. Genome drafting of nosocomial infection CREFrontiers in cellular and infection microbiology · 2024
    Article
  7. Article
  8. Colistin potentiation in multidrug-resistantFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Thea Brennan-Krohn *Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.ORCID 0000-0002-1284-0643
Alexandra Grote *Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Shade RodriguezDepartment of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.
James E Kirby *Department of Pathology, Beth Israel Deaconess Medical Centergrid.239395.7, Boston, Massachusetts, USA.ORCID 0000-0003-0392-4500
Ashlee M Earl *Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Beth Israel Deaconess Medical Center · USBroad Institute · US

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI CUOMO, CHRISTINA A · 2014 to 2024
$66.5M
INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
Pediatric Infectious Diseases Research TrainingT32HD055148 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI WESSELS, MICHAEL R · 2008 to 2018
$2.7M
Antimicrobial Synergy for Carbapenem-Resistant Enterobacteriaceae - Administrative SupplementK08AI132716 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BRENNAN-KROHN, THEA · 2018 to 2022
$916k
NIAID NIH HHS K08 AI132716NIAID NIH HHS T32 AI007061NIAID NIH HHS U19 AI110818NICHD NIH HHS T32 HD055148
6 · The paper itself

Abstract

Multidrug-resistant Gram-negative bacteria are a rapidly growing public health threat, and the development of novel antimicrobials has failed to keep pace with their emergence. Synergistic combinations of individually ineffective drugs present a potential solution, yet little is understood about the mechanisms of most such combinations. Here, we show that the combination of colistin (polymyxin E) and minocycline has a high rate of synergy against colistin-resistant and minocycline-intermediate or -resistant strains of Klebsiella pneumoniae. Furthermore, using transcriptome sequencing (RNA-Seq), we characterized the transcriptional profiles of these strains when treated with the drugs individually and in combination. We found a striking similarity between the transcriptional profiles of bacteria treated with the combination of colistin and minocycline at individually subinhibitory concentrations and those of the same isolates treated with minocycline alone. We observed a similar pattern with the combination of polymyxin B nonapeptide (a polymyxin B analogue that lacks intrinsic antimicrobial activity) and minocycline. We also found that genes involved in polymyxin resistance and peptidoglycan biosynthesis showed significant differential gene expression in the different treatment conditions, suggesting possible mechanisms for the antibacterial activity observed in the combination. These findings suggest that the synergistic activity of this combination against bacteria resistant to each drug alone involves sublethal outer membrane disruption by colistin, which permits increased intracellular accumulation of minocycline.

Indexed as

ColistinKlebsiella pneumoniaeAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialDrug SynergismMicrobial Sensitivity TestsMinocyclineTranscriptomeAnti-Bacterial AgentsColistinMinocyclineantibiotic resistanceantimicrobial activityantimicrobial agentsantimicrobial combinationsantimicrobial synergyRNA-Seqtranscriptomics

Identifiers

PMID35041511
PMCPMC8923212
OpenAlexW4220679621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.